drugset

drugset / Trial / NCT00209924

A Study of Gaboxadol in Primary Insomnia

NCT00209924 ↗

Phase 3 Completed 505 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.

Timeline

Start: 2004-04
Primary completion: —
Completion: 2005-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	gaboxadol	Small molecule	—	—

Indications